1. Introduction
Nairobi sheep disease (NSD) is a viral haemorrhagic fever disease affecting and inducing high mortality in sheep and goat populations [
1]. First reported in 1917 from an outbreak in Kenya [
2], subsequent outbreaks, including one in Uganda in 1958 [
3], have occurred when naïve animals lacking a pre-existing immunity have been moved from areas free from disease occurrence to regions where the disease is endemic. Once infected, a large number of animals are often lost, reaching in some instances ~90% mortality [
1]. The aetiological agent, the NSD virus (NSDV), is believed to circulate in East Africa (Kenya, Somalia, Uganda, and Tanzania) and Southern Asia (India, Sri Lanka, and China) [
4].
In terms of its phylogeny, NSDV is classified within the
Orthonairovirus genus of the
Nairoviridae family of the order
Bunyavirales. The virus is composed of three negative-sense RNA segments: small (S), encoding for the viral nucleoprotein (NP); medium (M), encoding for the viral glycoproteins; and long (L), encoding for the viral polymerase [
5]. Importantly, NSDV belongs to the same taxon as Crimean–Congo haemorrhagic fever virus (CCHFV), a zoonotic disease that is a threat to public health due to its ability to cause haemorrhagic fever in humans. CCHFV has a wide reported distribution, including countries in Africa, the Middle East, Southern Asia, and South-Eastern Europe [
6]. As a result, CCHFV distribution overlaps with NSDV.
In comparison with CCHFV, there are very few materials to study NSDV infection both in vitro and in vivo. In particular, a tool to monitor NSDV infection through staining of the virus NP, to decipher the viral tropism, would be useful [
7]. Additionally, in enzootic areas, a priority lies in distinguishing NSDV from the other orthonairoviruses that co-circulate in such regions. Such a task is complicated due to animals showing non-specific post-mortem clinical signs following an infection. According to the World Organisation of Animal Health (WOAH), the identification of the agent involved requires virus isolation in tissue culture (using a baby hamster kidney BHK21 cell line) followed by antigenic tests to confirm the presence of NSDV, with an immunofluorescence assay using a specific anti-NSDV antiserum being suitable for this purpose [
8]. However, a cross-reaction may occur with other members of the genus
Orthonairovirus, especially Dugbe virus (DUGV) [
9,
10]. Other methods such as RT-PCR are more specific in distinguishing viruses, although in some instances, cross-amplification with NSDV-specific primers can occur and has led to the discovery of Kupe virus (KUPV), a DUGV-related virus [
11].
In the present work, based on the alignment of members of the Nairoviridae family, we generate and characterise two monoclonal antibodies against a NSDV NP-derived peptide that displays a low sequence homology to other orthonairoviruses. We go on to demonstrate their ability to recognise NSDV NP without interacting with DUGV and CCHFV NPs. We believe our work provides a source for an anti-NSDV NP monoclonal antibody useful for research on NSDV and diagnostic analysis.
2. Materials and Methods
2.1. Nairovirus Alignment
An alignment of nairovirus NPs was produced at the amino acid level using the ClustalW algorithm in the software MEGA 7.0. A few members of each
Orthonairovirus species were aligned together, with the list of sequences used provided in
Table S1. Searching through the NP sequences of aligned viruses, regions of relatively high amino acid divergence (many mismatches in comparison to NSDV strains) were identified, with two candidates selected for mice immunisation.
2.2. Production of Mouse Monoclonal Antibodies
Peptide candidates were submitted to Bioserv UK, which performed monoclonal antibody production in mice. Ethical approval was obtained, with animal handling taken care of by the company, in accordance with United Kingdom regulations. A total of four mice were used (M1-4). Synthetic peptides from protein sequences exclusive to NSDV among orthonairoviruses, linked to carrier proteins such as Keyhole limpet hemocyanin (KLH), were used to hyperimmunise mice subcutaneously in the presence of a suitable adjuvant. Antisera were screened initially against each individual peptide. After termination, splenocytes from two out of four mice (M1 and M2) were isolated and fused with an immortalised cell line to create hybridomas. Such hybridomas were further cloned (limit dilution) and grown to a cell number sufficient to produce antibodies for the screening of the anti-NSDV NP hybridomas. Some of the best candidates, displaying a good response to NSDV peptides, were tested at The Pirbright Institute against NSDV-infected BHK21 cells to confirm reactivity to the antigen of interest. Two NSDV-reactive hybridomas were cultured and antibody scale-up production was performed, producing stock concentrations of 1 mg/mL for each monoclonal antibody.
2.3. Cell Lines
BHK21 cells were cultured in complete GMEM made of Glasgow minimum essential medium (GMEM) supplemented with foetal bovine serum (FBS; 10%), penicillin/streptomycin (100U; Cat # P4333, Sigma-Aldrich, Burlington, MA, USA), L-glutamine (2 mM; Cat # 59202C, Sigma-Aldrich), and tryptose phosphate broth (5%; Cat # T8159, Sigma-Aldrich) at 37 °C and 5% CO2.
2.4. NSDV Isolate and Viral Preparation
The NSDV isolate ND66 PC9 was obtained initially from World Reference [
12]. The virus was grown on BHK21 cells for three days before harvesting. Briefly, BHK21 were cultured in 175 cm
2 flasks until they reached 90–100% confluence. Cells were washed once in PBS, and 15 mL of virus inoculum (1:1000), prepared in FBS- and antibiotic-free GMEM, was applied onto the cells for an hour. The inoculum was then removed, and cells were cultured in 45 mL of complete GMEM containing 2% FBS. Cells were kept for 3 days until cytopathic effects (CPE) appeared. The medium containing virus particles was centrifuged at 3500×
g for 10 min to remove cellular debris. The supernatant was aliquoted and stored at −80 °C until use. Up to three vials were used to determine the average viral titre in distinct experiments, as described below. All experiments involving the handling of NSDV were performed within the Pirbright Institute’s Specified Animal Pathogens Order (SAPO) 4 containment laboratories.
2.5. Viral Titration in Supernatant
The amount of virus released in culture medium was measured as tissue culture infectious dose 50 (TCID50). Briefly, viral supernatant was 10-fold serial diluted from 1 to 1:100,000 in 50 μL of serum-free GMEM in a 96-well flat-bottom plate. Six replicates were used per dilution. An amount of 100 μL of complete GMEM containing 5 × 103 BHK21 cells was added per well. Cells were cultured for up to 4 days, monitoring the appearance of CPE. The last dilution at which CPE appeared in all wells and the number of wells displaying CPE in further dilutions were recorded, then the viral titre in TCID50/mL was obtained using the Spearman–Karber formula.
2.6. Immunofluorescent Assay (IFA)
BHK21 cells were plated at 3 × 105 cells/100 μL/well in a 96-well flat-bottom plate, in the presence of either 50 μL of NSDV at the equivalent of 105 TCID50/well or 50 μL of GMEM (uninfected control). The cells were cultured overnight at 37 °C and 5% CO2. Following incubation with the virus, the culture medium was discarded, and cells were fixed in the plate with 100 μL/well of cold methanol for 10 min. Cells were then washed three times with PBS before 100 μL/well of 2% BSA in PBS was added to the cells and incubated for an hour (blocking step). After blocking, 50 μL/well of supernatants from hybridoma cultures was added and left for an hour. The cells were washed three times with PBS; then, a secondary goat anti-mouse Alexa Fluor 488-conjugated antibody (Cat # A1101; Thermofisher scientific, Waltham, MA, USA) was used at 1:1000 for an hour. Finally, cells were washed, and staining was visualised using the IncuCyte® S3 Live-Cell Analysis System (Sartorius, Göttingen, Germany).
2.7. Nairobi Sheep Disease Virus Staining via Flow Cytometry
BHK21 cells were plated at 106 cells/well on a 6-well plate. Cells were infected by adding 2 mL of virus per well with a 5-fold decreasing virus titre per well—virus diluted in GMEM at 1:10 to 1:6250—and one well was kept uninfected (GMEM only). The cells were incubated overnight at 37 °C and 5% CO2, washed once with PBS, trypsinised, and harvested. Cells were fixed in 100 μL PFA 2% in PBS followed by permeabilisation in Triton X100 (0.1% in PBS), fixed and permeabilised using cytofix/cytoperm reagents (Cat # 555028, BD) according to the manufacturer’s instruction, or fixed and permeabilised in 100 μL cold methanol only, for 10 min. Cells were washed twice in PBS; then, a blocking step in 200 μL of 2% BSA in PBS was performed before an incubation with 50 μL solutions containing company-purified monoclonal antibodies. Cells were washed further in PBS before adding a secondary anti-mouse IgG FITC-conjugated antibody at 1:100. Finally, the cells were washed two times in PBS before being analysed in an LSR Fortessa II flow cytometer. To confirm the antibody isotype, secondary anti-mouse IgG1, IgG2a, or IgG2b were used.
2.8. Enzyme-Linked ImmunoSorbent Assay (ELISA)
Recombinant NSDV NP (Accession number: YP_009361831.1) was produced and provided by Reading University; DUGV NP (Accession number: Q8V336; Cat # CSB-EP851800DCAH-CSB) was from Stratech; and CCHFV NP (Accession number: NP_950237; Cat# REC31639) was from the Native Antigen Company, Oxford. Monoclonal antibodies were tested for their ability to bind NSDV, DUGV, and CCHFV NPs using ELISA. Briefly, wells of a Maxisorp plate (Cat # 44-2404-21, Thermo Fisher Scientific) were coated overnight with ~50 ng of protein per well of either NSDV NP, DUGV NP, or CCHFV NP. The plate was washed four times in PBS containing 0.05% Tween20 (PBST), blocked with PBST containing 4% skimmed milk (PBST-4% milk), and incubated for 45 min with monoclonal antibody diluted in PBST-4% milk. The plate was washed four times in PBST, and a secondary goat anti-mouse IgG antibody conjugated to HRP (Cat # A16072; Thermo Fisher Scientific) diluted 1:5000 in PBST-4% milk was added for 45 min. The plate was finally washed four times in PBST, before being developed using TMB (Cat # TMBW-1000-01; Cambridge bioscience, Cambridge, UK), and stopped using Stop solution (Cat # NSTP-1000-01; Cambridge bioscience).
2.9. Western Blot
Proteins were separated on a 12% polyacrylamide gel (Cat # 4561046; Biorad, Hercules, CA, USA) and then transferred onto a PVDF membrane (Cat # 1620177; Biorad). Membranes were blocked in PBS containing 10% skimmed milk (PBS-10% milk), followed by an incubation overnight at 4 °C with PBS-10% milk containing primary antibody at 1:1000. Membranes were washed and incubated at room temperature, with 1:5000 secondary anti-mouse HRP-conjugated antibody in PBS-10% milk for at least 1 h. Chemiluminescence was used to reveal blots.
4. Discussion
The generated anti-NSDV monoclonal antibodies GG12 and AF5 were shown to work well in the IFA test (see
Section 3.2) and, as a result, are suitable for assessing the presence of NSDV in samples upon virus isolation in BHK21, in accordance with WOAH guidelines [
8]. However, in order to validate the true potential of these monoclonal antibodies, their reactivity must be assessed against tissue samples derived from NSDV-infected sheep to account for any background.
Furthermore, since NSDV-derived peptides could be used as bait in an ELISA that reacted well with our antibodies directed against NSDV NP, it would be of great interest to assess the reactivity of sera derived from established NSDV-infected sheep that have undergone seroconversion [
13]. Such peptides may offer potential support materials for the development of ELISA-based diagnostic tests that are specific to NSDV among other orthonairoviruses.
Another challenge relies on assessing the presence of co-infecting agents in samples from exposed animals, especially in regions where more than one orthonairovirus circulates [
14]. Upon viral isolation, GG12 or AF5 monoclonal antibody used alongside another virus-specific antibody could offer a solution in these situations, provided that samples are collected in the timeframe when both viral agents are replicating within the exposed individuals. Finally, in the case of modelling the co-infection in vitro to assess the effect of such an event on all orthonairoviruses involved, our designated antibodies could allow for precise monitoring of the evolution of NSDV replication among others.